Overview
A Study of the Safety and Pharmacology of MEGF0444A in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors
Status:
Completed
Completed
Trial end date:
2013-04-01
2013-04-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
This is a Phase Ib, open-label, dose-escalation study of MEGF0444A in combination with bevacizumab, and in combination with bevacizumab and paclitaxel as therapy for locally advanced or metastatic solid tumors.Phase:
Phase 1Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Genentech, Inc.Treatments:
Albumin-Bound Paclitaxel
Bevacizumab
Paclitaxel
Criteria
Inclusion Criteria:- Histologically or cytologically documented, incurable, or metastatic solid malignancy
that has progressed on or failed to respond to regimens or therapies known to provide
clinical benefit
Specific to Arm A:
- For patients undergoing optional or mandatory exploratory MRI, at least one tumor
lesion that represents a liver, fixed peritoneal, neck, extremity, or pelvic lesion
measuring >/= 3 to 10 cm (for liver lesions) or >= 2 to 10 cm (for all other lesion
locations) to be used for MRI
Specific to Arm B:
- Maximum of two prior chemotherapy regimens for metastatic disease
Exclusion Criteria:
- Anti-cancer therapy within 3 weeks prior to initiation of study treatment
- Patients who had to discontinue prior bevacizumab therapy due to intolerable toxicity
- Leptomeningeal disease
- Active infection or autoimmune disease
- Known clinically significant liver disease, including active viral, alcoholic, or
other hepatitis, or cirrhosis
- Known primary central nervous system (CNS) malignancy or untreated or active CNS
metastases
- Inadequately controlled hypertension; history of hypertensive crisis or
encephalopathy; congestive heart failure (New York Heart Association Class II or
greater); history of myocardial infarction or unstable angina within 6 months prior to
initiation of study treatment
- History of hemoptysis; evidence of bleeding diathesis or significant coagulopathy
- History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess
within 6 months prior to initiation of study treatment
- Serious, non-healing wound, active gastrointestinal ulcer, or untreated bone fracture
Specific to Arm B:
- Known significant hypersensitivity to paclitaxel or other drugs using the vehicle
cremophor
- Previous intolerance to paclitaxel
- Grade >= 2 sensory neuropathy